Biosciences Institute, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom.
Front Endocrinol (Lausanne). 2020 Nov 17;11:594041. doi: 10.3389/fendo.2020.594041. eCollection 2020.
The Carbohydrate response element binding protein, ChREBP encoded by the gene, is a transcription factor that is expressed at high levels in the liver and has a prominent function during consumption of high-carbohydrate diets. ChREBP is activated by raised cellular levels of phosphate ester intermediates of glycolysis, gluconeogenesis and the pentose phosphate pathway. Its target genes include a wide range of enzymes and regulatory proteins, including , , , and enzymes of lipogenesis. ChREBP activation cumulatively promotes increased disposal of phosphate ester intermediates to glucose, glucose 6-phosphatase or to pyruvate glycolysis with further metabolism by lipogenesis. Dietary fructose is metabolized in both the intestine and the liver and is more lipogenic than glucose. It also induces greater elevation in phosphate ester intermediates than glucose, and at high concentrations causes transient depletion of inorganic phosphate, compromised ATP homeostasis and degradation of adenine nucleotides to uric acid. ChREBP deficiency predisposes to fructose intolerance and compromised cellular phosphate ester and ATP homeostasis and thereby markedly aggravates the changes in metabolite levels caused by dietary fructose. The recent evidence that high fructose intake causes more severe hepatocyte damage in ChREBP-deficient models confirms the crucial protective role for ChREBP in maintaining intracellular phosphate homeostasis. The improved ATP homeostasis in hepatocytes isolated from mice after chronic activation of ChREBP with a glucokinase activator supports the role of ChREBP in the control of intracellular homeostasis. It is hypothesized that drugs that activate ChREBP confer a protective role in the liver particularly in compromised metabolic states.
碳水化合物反应元件结合蛋白(ChREBP)由 基因编码,是一种转录因子,在肝脏中高表达,在高碳水化合物饮食中具有重要作用。ChREBP 被升高的磷酸酯中间代谢物激活,这些中间代谢物来自糖酵解、糖异生和磷酸戊糖途径。其靶基因包括多种酶和调节蛋白,包括 、 、 和脂生成酶。ChREBP 的激活累积促进了磷酸酯中间代谢物向葡萄糖、葡萄糖 6-磷酸酶或丙酮酸的转化,通过脂生成进一步代谢。膳食果糖在肠道和肝脏中都被代谢,比葡萄糖更具脂生性。它还比葡萄糖引起更高的磷酸酯中间代谢物升高,并且在高浓度下会导致无机磷酸盐暂时耗尽、ATP 稳态受损以及腺嘌呤核苷酸降解为尿酸。ChREBP 缺乏易患果糖不耐受和细胞内磷酸酯和 ATP 稳态受损,从而显著加剧了饮食果糖引起的代谢物水平变化。最近的证据表明,高果糖摄入在 ChREBP 缺乏模型中导致更严重的肝细胞损伤,证实了 ChREBP 在维持细胞内磷酸盐稳态方面的关键保护作用。用葡萄糖激酶激活剂慢性激活 ChREBP 后分离的肝细胞中 ATP 稳态的改善支持了 ChREBP 在控制细胞内稳态中的作用。有人假设,激活 ChREBP 的药物在肝脏中具有保护作用,特别是在代谢受损的状态下。